Tag: cells

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that dosing has commenced at the prestigious Weill Cornell Medicine Multiple Sclerosis Center in New York City, in its ongoing Phase 2 clinical trial evaluating intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). This fifth site complements existing sites at Yale University, Johns Hopkins University, Brigham and Women's Hospital, and the University of Massachusetts.

– Rademikibart significantly improved lung function and asthma control in patients with eosinophilic-driven type 2 asthma –

SAN FRANCISCO, CALIFORNIA, June 13, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE^® natural killer (NK) cell engager platform, today announced the appointment of David C. Mun-Gavin to its Board of Directors.

PARAMUS, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary continuous delivery technologies, announced today Gabrail Cancer Center (GCC) in Canton, Ohio is now activated and open for enrolling patients in its Phase 2a clinical trial evaluating their continuous low-dose lenalidomide, STAR-LLD, for the treatment of multiple myeloma (MM). Dr. Nash Gabrail, medical oncologist and founder of the Center, is the study’s lead investigator. Regional Medical Oncology Center, located in Wilson, NC, has also opened as the trial’s second active clinical site.

Data reported from the ongoing ATALANTA-1 Phase 1/2 study in a heavily pretreated relapsed refractory non-Hodgkin’s Lymphoma (R/R NHL) patient population demonstrate low rates of high-grade toxicities